- Home
- SVRA vs ORIC Comparison
SVRA vs ORIC Comparison
Compare SVRA & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SVRA | ORIC |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 861.3M |
| IPO Year | 2009 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SVRA | ORIC |
|---|---|---|
| Price | $4.97 | $7.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | $7.33 | ★ $19.73 |
| AVG Volume (30 Days) | 1.3M | ★ 1.5M |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $430.87 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.98 | $7.23 |
| 52 Week High | $7.01 | $14.93 |
Technical Indicators
Market Signals| Indicator | SVRA | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 43.97 | 41.43 |
| Support Level | $4.78 | $7.68 |
| Resistance Level | $5.43 | $9.13 |
| Average True Range (ATR) | 0.25 | 0.52 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 38.73 | 27.84 |
Price Performance
Historical ComparisonAbout SVRA Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.